Zai Lab says FDA grants orphan drug designation for DLL3 ADC zocilurtatug pelitecan in neuroendocrine carcinomas
ZLAB•FDA grants orphan designation for zocilurtatug pelitecan
Zai Lab says the FDA has granted orphan drug designation for zocilurtatug pelitecan, a DLL3-targeting ADC, in neuroendocrine carcinomas.
- The designation supports development in an area with no approved targeted therapies for previously treated patients.
- Zocilurtatug pelitecan previously received FDA fast track status for extrapulmonary NECs, plus fast track and orphan status in small cell lung cancer.
